{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Juarez-Rodriguez MD"],"funding":["NIAID NIH HHS"],"pagination":["798-814"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3264309"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["80(2)"],"pubmed_abstract":["Tuberculosis remains a global health threat, and there is dire need to develop a vaccine that is safe and efficacious and confers long-lasting protection. In this study, we constructed recombinant attenuated Salmonella vaccine (RASV) strains with plasmids expressing fusion proteins consisting of the 80 amino-terminal amino acids of the type 3 secretion system effector SopE of Salmonella and the Mycobacterium tuberculosis antigens early secreted antigenic target 6-kDa (ESAT-6) protein and culture filtrate protein 10 (CFP-10). We demonstrated that the SopE-mycobacterial antigen fusion proteins were translocated into the cytoplasm of INT-407 cells in cell culture assays. Oral immunization of mice with RASV strains synthesizing SopE-ESAT-6-CFP-10 fusion proteins resulted in significant protection of the mice against aerosol challenge with M. tuberculosis H37Rv that was similar to the protection afforded by immunization with Mycobacterium bovis bacillus Calmette-Guérin (BCG) administered subcutaneously. In addition, oral immunization with the RASV strains specifying these mycobacterial antigens elicited production of significant antibody titers to ESAT-6 and production of ESAT-6- or CFP-10-specific gamma interferon (IFN-?)-secreting and tumor necrosis factor alpha (TNF-?)-secreting splenocytes."],"journal":["Infection and immunity"],"pubmed_title":["Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system."],"pmcid":["PMC3264309"],"funding_grant_id":["R01 AI056289","AI 56289"],"pubmed_authors":["Clark-Curtiss JE","Arteaga-Cortes LT","Kader R","Juarez-Rodriguez MD","Curtiss R"],"additional_accession":[]},"is_claimable":false,"name":"Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system.","description":"Tuberculosis remains a global health threat, and there is dire need to develop a vaccine that is safe and efficacious and confers long-lasting protection. In this study, we constructed recombinant attenuated Salmonella vaccine (RASV) strains with plasmids expressing fusion proteins consisting of the 80 amino-terminal amino acids of the type 3 secretion system effector SopE of Salmonella and the Mycobacterium tuberculosis antigens early secreted antigenic target 6-kDa (ESAT-6) protein and culture filtrate protein 10 (CFP-10). We demonstrated that the SopE-mycobacterial antigen fusion proteins were translocated into the cytoplasm of INT-407 cells in cell culture assays. Oral immunization of mice with RASV strains synthesizing SopE-ESAT-6-CFP-10 fusion proteins resulted in significant protection of the mice against aerosol challenge with M. tuberculosis H37Rv that was similar to the protection afforded by immunization with Mycobacterium bovis bacillus Calmette-Guérin (BCG) administered subcutaneously. In addition, oral immunization with the RASV strains specifying these mycobacterial antigens elicited production of significant antibody titers to ESAT-6 and production of ESAT-6- or CFP-10-specific gamma interferon (IFN-?)-secreting and tumor necrosis factor alpha (TNF-?)-secreting splenocytes.","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Feb","modification":"2021-02-21T00:16:14Z","creation":"2019-03-27T00:48:20Z"},"accession":"S-EPMC3264309","cross_references":{"pubmed":["22144486"],"doi":["10.1128/IAI.05525-11","10.1128/iai.05525-11"]}}